The global lab-on-a-chip (LOC) market size is expected to reach USD 12.85 Billion at a steady CAGR of 10.6% in 2028, according to latest analysis by Emergen Research. Lab-on-a-chip market revenue growth is being steadily driven by increase in demand for point of care testing, rising prevalence of chronic diseases, and growing application of genomics and proteomics in cancer research. Proteomics is widely adopted for drug discoveries and biomarker. Rise in demand for personalized medicines is further driving Lab-on-a-chip market revenue growth, and the trend is expected to continue going ahead.
Lab-on-a-chip-based devices are the integration of several disciplines and miniaturization of laboratory procedures. These devices are branching out into additional aspects of healthcare such as stem cell, drug delivery, synthetic biology, and environmental monitoring owing to high level of integration required to develop LOC devices. Chronic diseases are on the rise globally. Rapidly increasing global geriatric population and changes in societal behavior are other factors leading to a steady increase in common and expensive long-term health problems. Adoption of lab-on-a-chip in the diagnosis of chronic diseases and infections are other major factors driving growth of the lab-on-a-chip market.
Key players in the market include Becton, Dickinson and Company, PerkinElmer, Inc., Bio-Rad Laboratories, Agilent Technologies, Inc., Thermo Fisher Scientific, Siemens Healthcare, Abaxis Inc., Roche Diagnostics, Abbott Laboratories, and Danaher Corporation.
To get leading market solutions, visit the link below: https://www.emergenresearch.com/industry-report/lab-on-a-chip-market